Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
COMMUNIQUÉ DE PRESSE Paris, le 28 février 2024 Résultats semestriels à fin décembre 2023 Entreprise à mission, Ramsay Santé poursuit son soutien pour la prise en charge de tous les...
-
PRESS RELEASE Paris, 28 February 2024 Half-year results at the end of December 2023 As a mission-driven company, Ramsay Santé continues its support for the care of all patients and...
-
Dregið verður úr fjárfestingum Ljósleiðarans þangað til niðurstaða fæst í hlutafjáraukningu félagsins en samkvæmt ársreikningi 2023, sem samþykktur var af stjórn í dag, var 570 milljóna króna halli á...
-
$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our...
-
Interim Report Q4 2023 EBITDA fixed herd prices (FHP) for Q4 2023 increased to 8.949 mEUR (Q4 2022: 5.292 kEUR), corresponding to an EBITDA margin FHP of 25.2% (Q4 2022: 15.2%). The quarterly EBITDA...
-
PLANO, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Rocky Mountain High Brands, Inc. (OTC: RMHB) today briefly explained last year’s quarterly results through September 30, 2023. The following is a...
-
EDMONTON, Alberta, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) today released financial results for the quarter and year ended December 31, 2023. Financial highlights ...
-
-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating...
-
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial...
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...